Affiliate Silver Bullet Review

Any organisation involved in today’s cut throat world of business, knows how important effective implementation is and how those slim margins determine whether or not an organisation will sink or swim. There are so many potential stumbling blocks that even the most experienced sales executive can miss the target, and yet it’s still important to focus on each one to move closer to a higher closing rate. When the sales executive is in the field, there is little that the business chief can do to alter the closing rate, but there is much to do in preparation and this should be a major area of focus.

To start off with, a sales executive must work to build the trust of a client. He or she must earn the trust and must do everything in their power to create the right impression, both personally and professionally. It will likely be necessary to engage, with numerous visits and interactions and be consistent at all times. At the very least, the executive must be prompt and attend all meetings on time, must call back as promised and follow-up any questions asked. The professional will be looking for the right information and will expect the sales executive to know what he or she is always talking about, without question. In the pharmaceutical industry, professionals and practitioners can be somewhat jaded and are used to dealing with executives from pharmaceutical companies that promise the earth, but don’t deliver. They are hesitant because they tend to believe that the representative is interested in sales and sales alone, and the barriers that may be established before the first meeting may be an additional hindrance to the establishment of this trust.

Once a position of trust is established and the potential client actually believes in the executive and sees potential for a future, there is more than just a foot in the door. This is not to say that sales will be a guarantee, but unless you reach this critical position you have very little chance of ever reaching the “Holy Grail.” A sales executive should never be afraid to call in testimonials from other established and happy customers, especially if the target has a personal experience with the provider.

Invariably, pharma consulting firms talk about the importance of effective implementation and the various tactics required to get the prospect to agree and to say “yes.” The modern-day sales executives should realise that most of the “old” techniques are so hackneyed that they should be laid to rest. After spending so much time building up trust with your prospects, trying to use any pressure tactics to exert sales, be they subliminal or not, can be disastrous. The executive has to realise that time is of the essence, because his or her effective use of this time will ultimately dictate whether that particular day represents profit to the employer, or loss. As a rule, pharmaceutical consultants have much experience in the various sales techniques, specific and pertinent to the industry. A pharmaceutical consulting firm is of great potential benefit to the parent organisation and can often help to ensure that effective implementation is front and centre to the sales executive’s approach.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.

As it’s estimated that the marketing of pharmaceutical products accounts for up to $25 billion of spending each year, there is a lot at stake for healthcare professionals everywhere. Understandably, a substantial amount of interest has arisen in the methodology used and the tactics employed by pharmaceutical companies as they deploy their sales organisations to contact and influence professionals. Some people feel that this industry requires more regulation and some factors have tried to influence the U.S. Congress to look more deeply into the business. This just goes to underline the professional and highly focused approach that the pharmaceutical company must take as it seeks to interact with the very people who are responsible for buying its products in sufficient numbers to ensure the long term success of its organisation.

Certain countries around the World have been quick to introduce legislation and restrictions governing how pharmaceutical companies may interact with professionals. Some countries such as Australia, for example, have established certain codes of conduct, setting standards for ethical marketing and insisting that member organisations comply with the requirements.

Pharmaceuticals sales executives will spend a lot of time involved in what is known as “detailing,” by visiting front line professionals and explaining how the product might work, giving market suggestions, likely product availability, how it should be dosed, side effects that could be expected and other details. This will require highly polished communication skills and sales executives must be able to overcome barriers to growth over the years due to distrust or suspicion. The sales executive has a pivotal role to play in helping to give the professional supplemental educational information. Much attention must be paid to these marketing methods by the pharmaceutical company.

If additional new regulations or restrictions develop in the near future, this would put even more emphasis on the need for effective marketing by the organisation. In these situations, pharmaceutical consulting firms should be employed by the company, as they have direct experience in the field and are ideally tuned to help educate the sales force to ensure that they do not meet any stumbling blocks, cross any lines or come away from any interaction with a professional without the most positive end result.

It may be necessary to disclose all types of interaction, any hospitality provided or suggested, any gifts or assistance given and the very nature of the education disseminated. Not only will it be necessary for the sales executive to be highly educated in the product itself, fully understanding of restrictions and implications, but the executive must also be fully able to market to their highest ability.

The majority of pharmaceutical consultants dedicate a lot of their time to providing the correct balance between product awareness and marketing and to training methods as well. Time management is an essential skill required and staff must be trained to make best use of it, just as traditional marketing skills must be a point of focus and any latest developments or new legal requirements included. In most cases, pharma consulting outsources these important areas, enabling company chiefs to focus on other core areas of concern. It’s important to understand how ineffective marketing may have a reputational consequence or even a punitive effect in this increasingly highly regulated arena and consultants can steer the organisation accordingly.

Alan Gillies is the CEO of L2L Consulting, a cutting-edge pharma consultancy firm which specialises in optimising productivity and performance within international companies by applying tailored organisational strategies.

How can it be possible for the senior management of a pharmaceutical company to be on the top of their game, when they have far too much to do? How can the shareholders of the organisation be sure that they are getting a sufficient return for equity if those charged with the responsibility of operating the company are working in an over packed environment. The pharmaceutical and healthcare business is one of the most challenging industries of all, as complex market forces interact to push an organisation that is not sufficiently focused off course. During times of rough weather, an experienced pharmaceutical consulting firm can assist the company to convert the promise of highly developed products into actual cash revenues to ensure longevity.

The pharmaceutical consulting company operates in a pressure packed environment, vulnerable to the attention of regulators, financiers and special-interest groups. The company is working to provide critical products which can literally mean the difference between life and death, yet must be keenly aware of the way that it operates and be careful not to step out of line in any way. If this is not pressure enough, the company must then venture into a marketplace which is full of additional pitfalls and loopholes, is highly competitive and is subject to a whole new raft of external forces. The smartest organisations will engage the services of a pharmaceutical consulting firm to help them survive and prosper. Such a firm is dedicated to understanding the difficulties facing the pharmaceutical company and to helping it succeed. In most cases, pharmaceutical consultants within this company are selected according to their levels of expertise, experience, ability and knowledge. These are not fresh-faced individuals with no experience of working on the streets, but can bring real world knowledge to bear on any given situation.

The pharmaceutical company executive does not have any spare time available due to a complex roster of tasks that must be addressed every day, so the consultant’s assistance in helping oversee sales force effectiveness is valued. The consultant will help to set up territory boundaries, to organise and motivate the sales team and to generally ensure that the entire operation is successful. A sales team must live and die according to its time management abilities and must maximise the time spent with potential customers and clients on a face-to-face basis. When time management is set up and effective, training will help to ensure the consulting firm infuses the sales executives strategically. Almost all pharma consulting firms are well aware that an agreement between the pharmaceutical company and medical professionals is a complex and two-way street and that financial considerations do not represent the entire game.

The consultant can play a pivotal role in the success of the company as 2010 unfolds. U.S. legislation is imminent and considerable challenges await as the industry unfolds the changes that will result. We’re about to undergo a most difficult period for a company in this sphere, but this can also be viewed as a potentially very lucrative period as well. The consultant will help to ensure that the pharmaceutical company’s glass is always more than half-full for the target company.

Alan Gillies is the Director of L2L Consulting, an elite pharmaceutical consultancy firm which specialises in Strategy Development and Implementation Excellence for prestigious multi-national organisations.

A good pharmaceutical company can be very proud of its overall contribution to the business of healthcare, as it spends much time and effort conceiving, developing and presenting new products to the marketplace. Such a company can spend enormous sums of money and many a late-night hour as it deals with the necessary consultation and lobbying, just as it puts up with endless layers of bureaucratic red tape. At the end of the day, effective implementation of the sales level is what will really makes a difference and dictates success. At the highest level of a pharmaceutical company, resources should be set aside to engage a pharmaceutical consulting firm, enabling you to focus on implementation and the achievement of meaningful results. These senior executives are busy people and should spend their precious time dealing with the development of their products and associated issues, with pharmaceutical consultants delegated to help with the necessary training, administration and implementation.

When a sales team member fails to ink a deal with a prospect, this is often to do with a poor understanding of the prospect’s problems, concerns and/or issues. The financial repercussions of a sale should be almost last on the list, yet it is often the principle concern. There is much competition in the market and sales do not happen just because a product is available. There may be many questions to answer and there will almost certainly be specific issues to address before the professional will be ready, willing and able to trust and engage with the business. A hard approach to selling will definitely not work in this arena and any sales executive who comes to the business from other industries should be given specific attention by the pharmaceutical consultant.

When interacting with the client, pitching the benefits of the product must await its particular time and place. There is a certain amount of hostility inherent in any potential relationship such as this at the early-stage and this has much to do with old-style hard sales tactics, lack of professionalism and distrust. This hostility can be difficult to overcome and one of the first tasks of the executive should be to build trust to enable the ratio of effective implementation to improve.

In our society, pharma consulting firms have current practice in the industry and know what it takes to break down the barriers that will certainly be addressed. Without a very focused approach to time management, territorial application and the training of sales techniques, to say nothing of product education, the company’s sales closure ratio will be inefficient. Against all these difficulties, margins are still narrow and so the company must ensure that its pharmaceutical sales team is as ready as possible to get out in the market and bring results, with little margin for error.

Motivation is important when it comes to the sales team’s results, but financial remuneration or a convoluted bonus structure should not be primary, rather job dedication and performance satisfaction should be powerful incentives themselves. The sales executive must clearly see that a deal consummation represents the beginning of a two-way and dynamic relationship with a new client and must not view the task ahead as a means of amassing financial gain alone.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.